Gossamer Bio receives an "Outperform" rating from Wedbush with a $4.00 price target.
Gossamer Bio, a clinical-stage biopharmaceutical firm, has received an "Outperform" rating from Wedbush with a $4.00 price target. Gossamer Bio is developing seralutinib for pulmonary arterial hypertension and GB002 for PAH treatment in Phase 3 trials. The company has a consensus "Buy" rating and a $9.20 average target price, with significant institutional investor interest. Analysts' Q3 2024 earnings per share estimates range from ($0.17) to ($0.23) per share.
August 17, 2024
3 Articles